eFFECTOR Therapeutics (EFTR) News Today $0.0002 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period eFFECTOR Therapeutics (OTC:EFTR) Stock, Insider Trading ActivityOctober 5, 2024 | benzinga.com3 Publicly Traded Companies Filing for Bankruptcy as July Kicks OffJuly 15, 2024 | investorplace.comeFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from NasdaqJune 24, 2024 | globenewswire.comeFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian CancerMay 20, 2024 | globenewswire.comEFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024May 9, 2024 | investorplace.comeFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | globenewswire.comeFFECTOR Therapeutics to Participate in Upcoming Investor ConferenceApril 9, 2024 | globenewswire.comEFFECTOR Therapeutics Shares Drop as Development of Lung Cancer Treatment Drug EndsApril 4, 2024 | marketwatch.comEFFECTOR Reports Results Of Phase2 KICKSTART Trial Of Tomivosertib-Pembrolizumab In NSCLCApril 4, 2024 | markets.businessinsider.comCancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing DataApril 4, 2024 | finance.yahoo.comTrading was temporarily halted for "EFTR" at 10:04 AM with a stated reason of "LULD pause."April 4, 2024 | marketbeat.comTrading was temporarily halted for "EFTR" at 09:04 AM with a stated reason of "LULD pause."April 4, 2024 | marketbeat.comeFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung CancerApril 4, 2024 | globenewswire.comTrading was temporarily halted for "EFTR" at 08:04 AM with a stated reason of "News pending."April 4, 2024 | marketbeat.comBuy Rating for eFFECTOR Therapeutics Backed by Solid Financials and Promising Zotatifin TrialsMarch 28, 2024 | markets.businessinsider.comeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 27, 2024 | finanznachrichten.deEFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023March 25, 2024 | investorplace.comeFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 25, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE)March 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for eFFECTOR Therapeutics Amid Promising Oncology Drug Milestones and Extended Financial RunwayFebruary 6, 2024 | markets.businessinsider.comeFFECTOR Therapeutics Regains Nasdaq Compliance StatusJanuary 31, 2024 | msn.comDoes eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?January 30, 2024 | finance.yahoo.comeFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesJanuary 25, 2024 | finance.yahoo.comTrading was temporarily halted for "EFTR" at 07:01 PM with a stated reason of "News pending."January 12, 2024 | marketbeat.comeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Announces Reverse Stock SplitJanuary 10, 2024 | finanznachrichten.deeFFECTOR Therapeutics announces 1-for-25 reverse stock splitJanuary 9, 2024 | msn.comeFFECTOR Therapeutics Discloses Updated Data From Mid-Stage Breast Cancer StudyDecember 8, 2023 | msn.comeFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer PatientsDecember 8, 2023 | finance.yahoo.comeFFECTOR stock rises after FDA fast track status for breast cancer therapyNovember 28, 2023 | msn.comBuy Rating for eFFECTOR Therapeutics Based on Promising Drug Developments and Capital SecurityNovember 17, 2023 | markets.businessinsider.comeFFECTOR Therapeutics GAAP EPS of -$0.13 misses by $0.01November 13, 2023 | msn.comeFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 13, 2023 | tmcnet.comeFFECTOR Therapeutics (NASDAQ: EFTR)September 20, 2023 | fool.comHC Wainwright starts eFFECTOR at buy, cites drug technology platformAugust 25, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of eFFECTOR Therapeutics (EFTR) with Buy RecommendationAugust 24, 2023 | nasdaq.comeFFECTOR Stock To Rally Over 500%? Analyst Predict Blockbuster Status For Cancer CandidatesAugust 24, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR) and Brainsway (BWAY)August 24, 2023 | markets.businessinsider.comeFFECTOR Therapeutics Chief Executive Officer Acquires 33,799 Shares After Exercising Company Stock OptionsAugust 14, 2023 | benzinga.comeFFECTOR Therapeutics First Half 2023 Earnings: US$0.41 loss per share (vs US$0.093 loss in 1H 2022)August 11, 2023 | finance.yahoo.comMizuho Securities Reaffirms Their Buy Rating on eFFECTOR Therapeutics (EFTR)August 9, 2023 | markets.businessinsider.comeFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 8, 2023 | finance.yahoo.comeFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct OfferingsJune 8, 2023 | finance.yahoo.comeFFECTOR Therapeutics to launch ~$8.7M registered direct offeringJune 7, 2023 | msn.comeFFECTOR Therapeutics Shares Fall Premarket After Stock Sale >EFTRJune 7, 2023 | marketwatch.comInvestors in eFFECTOR Therapeutics (NASDAQ:EFTR) from a year ago are still down 35%, even after 77% gain this past weekJune 3, 2023 | finance.yahoo.comeFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 31, 2023 | finance.yahoo.comStifel Upgrades eFFECTOR Therapeutics (EFTR)May 26, 2023 | msn.comWhy eFFECTOR Therapeutics Shares Trading Higher TodayMay 26, 2023 | msn.comeFFECTOR soars as Stifel upgrades after Phase 2 data for cancer drug comboMay 26, 2023 | msn.comeFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 26, 2023 | finance.yahoo.com Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now EFTR Media Mentions By Week EFTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EFTR News Sentiment▼0.000.48▲Average Medical News Sentiment EFTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EFTR Articles This Week▼00▲EFTR Articles Average Week Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alvotech News biote News BriaCell Therapeutics News Clever Leaves News Fortress Biotech News GeoVax Labs News LAVA Therapeutics News Mainz Biomed News Pharvaris News Procaps Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EFTR) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredCan Trump Make Housing Great Again?Trump won. But can he undo the damage the Democrats have inflicted on this nation? Under Biden, inflatio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
